Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004186722> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2004186722 abstract "Introduction: ABT‐737 is a BH3 mimetic that selectively inhibits Bcl‐2, Bcl‐xL and Bcl‐w and has been shown to induce apoptosis in several tumor types. Mcl‐1 expression has been proposed as a potential mechanism of resistance to Mcl‐1. Sorafenib is an oral multikinase inhibitor that targets VEGFR2, PDGFR, B‐Raf and has also been shown to down modulate Mcl‐1. PLX4720 is a potent inhibitor of the V600E mutant B‐Raf which is an oncogenic activating mutation that is found in approximately 40–60% of patients with cutaneous melanoma. PLX4032, a similar and more bioavailable molecule than PLX4720, is currently in clinical development and was associated with clinical responses in patients with malignant melanoma in a phase I trial. Since we have previously shown that sorafenib has a synergistic effect when used in combination with ABT‐737, we set out to evaluate and compare the effects of sorafenib and PLX4720 alone and in combination with ABT‐737 on melanoma cell lines. Methods: The B‐Raf V600E mutant melanoma cell lines A375, A2058 and SKMEL5 were treated with DMSO, sorafenib (10 uM) or PLX4720 (1 uM) alone or in combination with ABT‐737 (5 uM). Cell lysates were prepared after 4 hours and probed with specific antibodies to detect the presence of vinculin, PARP, Mcl‐1, total Erk, and phosphorylated Erk (Thr202/Tyr204) using standardWestern Blot technique. In addition, cells treated for 24 hours were assessed for cytotoxic activity using propidium iodide staining followed by flow cytometeric analysis. Results: Results were broadly similar in all three cell lines tested. Both sorafenib and PLX4720, but not ABT‐737, were found to down‐modulate Mcl‐1 and the phosphorylation of Erk (pErk). The effect of PLX4720 on Erk phosphorylation was greater than the effect of sorafenib while, conversely, sorafenib‐downmodulation of Mcl‐1 was more profound than that of PLX4720. PARP cleavage was identified in ABT‐737 treated cells at a low level, however this was substantially enhanced in combination with either sorafenib or PLX4720. Cytotoxicity was greater in sorafenib‐treated cells than those treated with PLX4720. The effect of each treatment was enhanced, however, in combination with ABT‐737, which exhibited little to no single‐agent activity across all cell lines. The combination of sorafenib and ABT‐737 had the strongest cytotoxic effect of the treatments evaluated in each cell line. Conclusion: Both the multitargeted TKI sorafenib and the more specific V600E mutant B‐raf inhibitor PLX4720 enhance the cytotoxicity of the BH3‐mimetic ABT‐737 in melanoma cell lines. Our results suggest that ABT‐737‐mediated cytotoxicity is dependent on Mcl‐1 downmodulation. This is supported by the finding that the combination of sorafenib and ABT‐737 is more toxic than PLX4720 and ABT‐737 and is associated with a more effective reduction of Mcl‐1 levels in 4 hour lysates. Xenograft testing of these combinations is planned with the goal of translating the most successful combination into an early phase clinical trial. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B89." @default.
- W2004186722 created "2016-06-24" @default.
- W2004186722 creator A5008479799 @default.
- W2004186722 creator A5058918536 @default.
- W2004186722 creator A5061578231 @default.
- W2004186722 creator A5066250381 @default.
- W2004186722 creator A5083614176 @default.
- W2004186722 date "2009-12-10" @default.
- W2004186722 modified "2023-09-26" @default.
- W2004186722 title "Abstract B89: The effects of raf kinase inhibition with either sorafenib or PLX‐4720 on Mcl‐1 expression and cytotoxicity alone and in combination with ABT‐737 in melanoma cell lines" @default.
- W2004186722 doi "https://doi.org/10.1158/1535-7163.targ-09-b89" @default.
- W2004186722 hasPublicationYear "2009" @default.
- W2004186722 type Work @default.
- W2004186722 sameAs 2004186722 @default.
- W2004186722 citedByCount "1" @default.
- W2004186722 countsByYear W20041867222013 @default.
- W2004186722 crossrefType "proceedings-article" @default.
- W2004186722 hasAuthorship W2004186722A5008479799 @default.
- W2004186722 hasAuthorship W2004186722A5058918536 @default.
- W2004186722 hasAuthorship W2004186722A5061578231 @default.
- W2004186722 hasAuthorship W2004186722A5066250381 @default.
- W2004186722 hasAuthorship W2004186722A5083614176 @default.
- W2004186722 hasConcept C184235292 @default.
- W2004186722 hasConcept C185592680 @default.
- W2004186722 hasConcept C190283241 @default.
- W2004186722 hasConcept C2775934118 @default.
- W2004186722 hasConcept C2777658100 @default.
- W2004186722 hasConcept C2778019345 @default.
- W2004186722 hasConcept C2778695046 @default.
- W2004186722 hasConcept C31573885 @default.
- W2004186722 hasConcept C502942594 @default.
- W2004186722 hasConcept C54355233 @default.
- W2004186722 hasConcept C55493867 @default.
- W2004186722 hasConcept C57074206 @default.
- W2004186722 hasConcept C71924100 @default.
- W2004186722 hasConcept C81885089 @default.
- W2004186722 hasConcept C86803240 @default.
- W2004186722 hasConcept C98274493 @default.
- W2004186722 hasConceptScore W2004186722C184235292 @default.
- W2004186722 hasConceptScore W2004186722C185592680 @default.
- W2004186722 hasConceptScore W2004186722C190283241 @default.
- W2004186722 hasConceptScore W2004186722C2775934118 @default.
- W2004186722 hasConceptScore W2004186722C2777658100 @default.
- W2004186722 hasConceptScore W2004186722C2778019345 @default.
- W2004186722 hasConceptScore W2004186722C2778695046 @default.
- W2004186722 hasConceptScore W2004186722C31573885 @default.
- W2004186722 hasConceptScore W2004186722C502942594 @default.
- W2004186722 hasConceptScore W2004186722C54355233 @default.
- W2004186722 hasConceptScore W2004186722C55493867 @default.
- W2004186722 hasConceptScore W2004186722C57074206 @default.
- W2004186722 hasConceptScore W2004186722C71924100 @default.
- W2004186722 hasConceptScore W2004186722C81885089 @default.
- W2004186722 hasConceptScore W2004186722C86803240 @default.
- W2004186722 hasConceptScore W2004186722C98274493 @default.
- W2004186722 hasLocation W20041867221 @default.
- W2004186722 hasOpenAccess W2004186722 @default.
- W2004186722 hasPrimaryLocation W20041867221 @default.
- W2004186722 hasRelatedWork W1414915294 @default.
- W2004186722 hasRelatedWork W1601647392 @default.
- W2004186722 hasRelatedWork W1626821504 @default.
- W2004186722 hasRelatedWork W2013849893 @default.
- W2004186722 hasRelatedWork W2055695980 @default.
- W2004186722 hasRelatedWork W2069912173 @default.
- W2004186722 hasRelatedWork W2083681983 @default.
- W2004186722 hasRelatedWork W2111281816 @default.
- W2004186722 hasRelatedWork W2257157366 @default.
- W2004186722 hasRelatedWork W2269888391 @default.
- W2004186722 hasRelatedWork W2319328441 @default.
- W2004186722 hasRelatedWork W2331761697 @default.
- W2004186722 hasRelatedWork W2337923700 @default.
- W2004186722 hasRelatedWork W2340300548 @default.
- W2004186722 hasRelatedWork W2395292353 @default.
- W2004186722 hasRelatedWork W2550959716 @default.
- W2004186722 hasRelatedWork W2586567488 @default.
- W2004186722 hasRelatedWork W2902413705 @default.
- W2004186722 hasRelatedWork W2967362211 @default.
- W2004186722 hasRelatedWork W2979572678 @default.
- W2004186722 isParatext "false" @default.
- W2004186722 isRetracted "false" @default.
- W2004186722 magId "2004186722" @default.
- W2004186722 workType "article" @default.